GW1929

GW1929
  • CAS No.:196808-24-9
Other grades of this product :
GW1929 Basic information
Product Name:GW1929
Synonyms:GW1929;GW1929 HYDRATE;N-(2-Benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-L-tyrosine hydrate;(2S)-2-(2-benzoylanilino)-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanoic acid;(S)-2-(2-Benzoylphenylamino)-3-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)propanoic acid;GW 1929 hydrochloride;N-(2-Benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-L-tyrosinehydrochloride;N-(2-BENZOYLPHENYL)-O-[2-(METHYL-2-PYRIDINYLAMINO)ETHYL]-L-TYROSINE
CAS:196808-24-9
MF:C30H29N3O4
MW:495.57
EINECS:
Product Categories:Intracellular receptor
Mol File:196808-24-9.mol
GW1929 Chemical Properties
Boiling point 749.2±60.0 °C(Predicted)
density 1.264±0.06 g/cm3(Predicted)
storage temp. Desiccate at +4°C
solubility DMSO: 20 mg/mL
pka3.91±0.10(Predicted)
form solid
color yellow
InChIKeyQTQMRBZOBKYXCG-MHZLTWQESA-N
Safety Information
WGK Germany 3
MSDS Information
GW1929 Usage And Synthesis
DescriptionPeroxisome proliferator-activated receptor (PPAR) γ is a nuclear receptor that, when activated, regulates fatty acid storage and glucose metabolism. The best known class of PPARγ ligands are the thiazolidinediones, including troglitazone and rosiglitazone . GW 1929 is a non-thiazolidinedione activator of PPARγ that binds with a Ki value of 1.4 nM, with greater than 1,000-fold selectivity over other PPAR subtypes. It has anti-hyperglycemic and anti-hyperlipidemic activity when given orally in mouse and rat models of type 2 diabetes. Both in vitro and in vivo effects of GW 1929 on PPARγ greatly exceed those produced by troglitazone. In addition, GW 1929 has neuroprotective effects in global cerebral ischemic-reperfusion injury that are related to reduced inflammation and apoptotic DNA fragmentation.
UsesPeroxisome proliferator-activated receptor (PPAR) γ is a nuclear receptor that, when activated, regulates fatty acid storage and glucose metabolism. The best known class of PPARγ ligands are the thiazolidinediones, including troglitazone and rosiglitazone . GW 1929 is a non-thiazolidinedione activator of PPARγ that binds with a Ki value of 1.4 nM, with greater than 1,000-fold selectivity over other PPAR subtypes. It has anti-hyperglycemic and anti-hyperlipidemic activity when given orally in mouse and rat models of type 2 diabetes. Both in vitro and in vivo effects of GW 1929 on PPARγ greatly exceed those produced by troglitazone. In addition, GW 1929 has neuroprotective effects in global cerebral ischemic-reperfusion injury that are related to reduced inflammation and apoptotic DNA fragmentation.[Cayman Chemical]
UsesGW1929 has been used as a peroxisome proliferator-activated receptor γ (PPARγ) ligand:
  • to study its effects on plant homeodomain finger protein 16 (Phf16) and patatin-like phospholipase domain containing 3 (Pnpla3) expression involved in adipogenesis
  • to study its effects on complement component 3 (C3) gene expression in human hepatoma cells
  • to activate PPARγ in human breast cancer cells
Biological ActivityHighly selective orally active peroxisome proliferator-activated receptor (PPAR) γ agonist (pEC 50 values are 8.05, < 4 and < 4 for human PPAR γ , PPAR α and PPAR δ receptors respectively). Decreases glucose, fatty acid and triglyceride levels following oral administration in vivo .
Biochem/physiol ActionsGW1929 is a non-thiazolidinedione and is involved in cell growth inhibition and regulating gene expression. It exhibits neuroprotective effects against global cerebral ischemic-reperfusion injury by DNA fragmentation and minimizing the inflammation. GW1929 participates in the inhibition of α7 N-acetylcholine receptor expression and promoter activity. It also influences the early growth response-1 (Egr-1) protein expression.
in vitrogw1929 was tested on currents through l-type voltage-dependent calcium channels (vdcc) in freshly isolated smooth muscle cells. using ba2+ as the charge carrier through vdcc, the ic50s for gw1929 and pioglitazone were determined to be 5.0 +/- 0.7 and 10.0 +/- 0.8 μm, respectively. gw1929 and pioglitazone were both effective on inhibiting vdcc and relaxing pressurized arteries, indicating the vasodilation of resistance arteries might be explained by the inhibition of calcium entry through vdcc [1].
in vivogw1929 treatment attenuated the neurological damage in focal cerebral ir injury significantly. in addition, the neuroprotective effects of gw1929 were found to be associated with significant reduction in the levels of mmp-9, cox-2, inos, tnfα and il-6. neuroprotective effects of gw1929 related with significant reduction in tunel positive cells in ir challenged brain [2].
IC 505.0 μm
references[1] heppner tj,bonev ad,eckman dm,gomez mf,petkov gv,nelson mt. novel ppargamma agonists gi 262570, gw 7845, gw 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. pharmacology.2005 jan;73(1):15-22. [2] kaundal rk,sharma ss. ameliorative effects of gw1929, a nonthiazolidinedione pparγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. curr neurovasc res.2011 aug 1;8(3):236-45.
GW1929 Preparation Products And Raw materials

Welcome!

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

  • NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
  • +86-23-6139-8061 +86-13650506873
  • danny@chemdad.com sales@chemdad.com
  • www.chemdad.com
  • WhatsApp +86-13650506873

Name

phone

company

email

message

Payment methods
Google translate: 日本语日本语 한국어한국어 FrançaisFrançais DeutschDeutsch EspañaEspaña TürkiyeTürkiye